Cell-Based Assay and High Content Screening Markets: Market Forecasts by Application with Executive and Consultant Guides, Including Customized Forecasting and Analysis 2022 to 2026
Cell Based Assays (CBAs) are a mainstay of drug development and scientific research, but growth is now accelerating as the race for a COVID-19 cure gains speed. On top of this new technology is allowing CBAs to be used to measure any aspect of cell function. This market just keeps on growing with no end in sight. The workhorse of the pharmaceutical industry is becoming a central player in biotechnology.
This is a complex area however this readable report will bring the entire management team up to speed, on both the technology and the opportunity.
The technology is moving faster than the market. Genomics and Immunology are playing a role too. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
All report data is available in Excel format on request with the corporate license.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options, however your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
Assistance and additional breakout data relevant to your own area(s) of interest is available free of charge with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School